Company intelligence / Profile preview

睿健医药科技

Wuhan, Hubei, China

Ownership: Private
Development stage: Other

Overview

RuiJian Medicine is a clinical-stage biotechnology company specializing in the development of chemically induced functional cell therapies derived from induced pluripotent stem cells (iPSCs). The company utilizes a proprietary AI-driven platform to precisely control cell fate, enabling the large-scale production of high-purity, standardized cell products. Its lead program, N-001, is a dopamine neuron precursor therapy currently in clinical trials for the treatment of Parkinson's disease. Beyond neurodegenerative disorders, RuiJian is expanding its pipeline to address spinal cord injuries, ophthalmic diseases, and metabolic conditions.

Therapeutic areas: GastroenterologyNeurologyOphthalmology
Modalities: Induced pluripotent stem cell derived therapyCell therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on 睿健医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 睿健医药科技.

Explore the full profile